{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2015-12-08&_metadata=all&answer.answeringMemberPrinted=George+Freeman", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=0&max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman", "items" : [{"_about" : "http://data.parliament.uk/resources/436264", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/436264/answer", "answerText" : {"_value" : "<br /><p>The Interim Report of Sir Hugh Taylor\u2019s Accelerated Access Review (AAR) is a deliberately high level document that indicates direction of travel; as such, government will be responding to the AAR\u2019s conclusions when its final recommendations are published early in the spring of 2016.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T16:30:10.483Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether he plan to respond to the Accelerated Access Review: Interim Report, published in October 2015; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "19241"}
    , {"_about" : "http://data.parliament.uk/resources/436265", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/436265/answer", "answerText" : {"_value" : "<p>NHS England and the National Institute for Health and Care Excellence are currently consulting jointly on draft proposals on the future direction of the Cancer Drugs Fund.<\/p><br /><p>The consultation was published on 19 November 2015 and is open until 11 February 2016. It states that it is looking to put in place a solution that ensures patients have routine access to a greater range of cancer drugs, including earlier access to innovative drugs, while ensuring that cost-effectiveness is maintained. Further information is available at:<\/p><p>www.engage.england.nhs.uk/consultation/cdf-consultation<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-15T16:22:51.767Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Leukaemia: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, if he will ensure that the new Cancer Drugs Fund will increase patient access to medicines for acute myeloid leukaemia.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "19240"}
    , {"_about" : "http://data.parliament.uk/resources/434007", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/434007/answer", "answerText" : {"_value" : "<p>NHS England has advised that a draft treatment pathway for patients with multiple myeloma, which takes into account the potential impact of treatments removed from the Cancer Drugs Fund (CDF), is currently being finalised. It is likely to be published early in 2016.<\/p><br /><p>The Government remains committed to the Fund. NHS England and the National Institute for Health and Care Excellence are currently consulting on draft proposals on the future direction of the CDF. The consultation is open until 11 February 2016 and further information is available at:<\/p><br /><p>www.engage.england.nhs.uk/consultation/cdf-consultation<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-10T14:17:08.253Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Multiple Myeloma: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to ensure that the treatment of patients with multiple myeloma is not affected by the (a) delisting of treatments from the Cancer Drugs Fund and (b) ongoing consultation on that Fund's future.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "18734"}
    , {"_about" : "http://data.parliament.uk/resources/434008", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/434008/answer", "answerText" : {"_value" : "<p>NHS England and the National Institute for Health and Care Excellence are currently consulting on draft proposals on the future direction of the Cancer Drugs Fund (CDF). The consultation is open until 11 February 2016 and further information is available at:<\/p><br /><p>www.engage.england.nhs.uk/consultation/cdf-consultation<\/p><br /><p>The Accelerated Access Review independently chaired by Sir Hugh Taylor, is working with key stakeholders on a range of options for accelerating patient access to innovative products, as set out in the interim report. This includes consideration of the impact of managed access schemes such as proposed in the CDF consultation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-12-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-12-10T14:04:50.203Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-12-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to ensure the outcome of the consultation on the future of the Cancer Drugs Fund is co-ordinated with and complements the recommendations of the Accelerated Access Review to ensure improved patient access to innovative treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "18766"}
    , {"_about" : "http://data.parliament.uk/resources/428358", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/428358/answer", "answerText" : {"_value" : "<p>NHS England has advised that it intends to jointly consult with the National Institute for Health and Care Excellence on proposals for a new Cancer Drugs Fund operating model. This will include the future arrangements for the evaluation of cancer drugs, including drugs for rarer cancers with small patient populations. Members of the public and any interested parties will have the opportunity to consider and comment on these proposals.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-11-23", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "16188"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-11-23T10:58:14.527Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-11-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to improve the assessment of medicines for rarer cancers with small patient populations.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "16497"}
    , {"_about" : "http://data.parliament.uk/resources/226307", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/226307/answer", "answerText" : {"_value" : "<p>Since 24 November 2014, there have been no discussions between my Rt. Hon. Friend the Secretary of State for Health and NHS England on its revised approach to promoting and taking account of research in the new healthcare system. However, discussions between senior officials in the Department and NHS England are ongoing.<\/p><p> <\/p><p> <\/p><p> <\/p><p>NHS England will be setting out high level plans through their Business Plan, which is due to be published on 27 March 2015. NHS England does not routinely consult on business plans and, as such, no formal consultation has been planned.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-03-17", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "227008"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-03-17T16:19:17.01Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-03-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Research"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 24 February 2015 to Question 223768, on which dates since 24 November 2014 he has discussed with NHS England its revised approach to promoting and taking account of research in the new healthcare system; and what the content of those discussions was.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "227007"}
    , {"_about" : "http://data.parliament.uk/resources/226308", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/226308/answer", "answerText" : {"_value" : "<p>Since 24 November 2014, there have been no discussions between my Rt. Hon. Friend the Secretary of State for Health and NHS England on its revised approach to promoting and taking account of research in the new healthcare system. However, discussions between senior officials in the Department and NHS England are ongoing.<\/p><p> <\/p><p> <\/p><p> <\/p><p>NHS England will be setting out high level plans through their Business Plan, which is due to be published on 27 March 2015. NHS England does not routinely consult on business plans and, as such, no formal consultation has been planned.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-03-17", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "227007"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-03-17T16:19:16.887Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-03-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Research"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 24 February 2015 to Question 223768, when NHS England plans to publish its revised approach to promoting and taking account of research in the new healthcare system; and what plans NHS England has to hold a formal consultation on that revised approach.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "227008"}
    , {"_about" : "http://data.parliament.uk/resources/178540", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/178540/answer", "answerText" : {"_value" : "<p>The consultation for the NHS England Research and Development Strategy closed in December 2013. NHS England subsequently decided not to publish the results of the consultation at that time, but instead to use the findings to inform a new piece of work which would be developed with the Department which will describe NHS England\u2019s role in promoting and taking account of research in the new healthcare system.<\/p><p> <\/p><p> <\/p><p> <\/p><p>NHS England is working with the Department to agree a revised approach.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Delivery of NHS England\u2019s research objective was discussed at the accountability meeting on 14 October 2014. The minutes of this meeting are available at:<\/p><p> <\/p><p> <\/p><p> <\/p><p><a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/377477/SofS_Accountability_Meeting_oct_2014.pdf\" target=\"_blank\">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/377477/SofS_Accountability_Meeting_oct_2014.pdf<\/a><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-02-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-02-24T16:49:23.607Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-02-09", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Research"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, when he expects to publish the results of the consultation for the NHS England Research and Development Strategy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "223768"}
    , {"_about" : "http://data.parliament.uk/resources/174759", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/174759/answer", "answerText" : {"_value" : "<p>The Department has not commissioned any research relating specifically to cholangiocarcinoma. The National Institute for Health Research Imperial Biomedical Research Centre has a £3.6 million gastroenterology and hepatology research theme (2012-17). This includes research on cholangiocarcinoma biomarkers and imaging.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-01-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-01-27T12:35:01.583Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-01-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Bile Duct Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what research his Department has commissioned into cholangiocarcinoma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "221396"}
    , {"_about" : "http://data.parliament.uk/resources/155948", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/155948/answer", "answerText" : {"_value" : "<p>Most new medicines for rare conditions are licensed by the European Commission.<\/p><p> <\/p><p>The European Union offers a range of incentives to encourage the development of these medicines in order to address unmet clinical need. These incentives include a period of 10 years market exclusivity, the provision of Protocol Assistance (scientific advice specifically tailored for orphan medicinal products) and fee reductions and waivers for regulatory procedures.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Through the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom takes an active role in the decision making process at the European Medicines Agency\u2019s Committee on Orphan Medicinal Products, ensuring applications for Orphan Drug designation of potential drug candidates for rare diseases are appropriately recognised, encouraging companies to develop their products further and recommending use of existing flexibilities such as conditional authorisation, authorisation under exceptional circumstances and accelerated assessment. The UK is actively involved in the European Medicines Agency\u2019s adaptive licensing pilot that is exploring further use of these flexibilities. The MHRA has an Innovation Office that can offer advice and assistance to developers of drugs for rare diseases, including on the use of flexibilities.<\/p><p> <\/p><p><strong> <\/strong><\/p><p> <\/p><p>In addition, in the UK, the Early Access to Medicines Scheme aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.<\/p><p> <\/p><p> <\/p><p> <\/p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.<\/p><p> <\/p><p><strong> <\/strong><\/p><p> <\/p><p><strong> <\/strong><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-11-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-11-24T17:23:13.99Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-11-17", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prescription Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what steps his Department is taking to encourage flexibility in the licensing process for potential new treatments for rare conditions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "214491"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=1&max-date=2015-12-08&answer.answeringMemberPrinted=George+Freeman", "page" : 0, "startIndex" : 1, "totalResults" : 11, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}